Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 10, 2012, Pages 3744-3750

  Gaudio, Agostino ^a   Privitera, Filippo ^a   Battaglia, Katia ^a   Torrisi, Venerando ^b   Sidoti, Maria Helga ^a   Pulvirenti, Ivana ^a   Canzonieri, Elena ^a   Tringali, Giovanni ^b   Fiore, Carmelo Erio ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Istituto Ricerca Medica Ambientale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIDIABETIC AGENT; BETA CATENIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; DICKKOPF 1 PROTEIN; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; HEMOGLOBIN A1C; INSULIN; PHOSPHATASE; SCLEROSTIN; WNT PROTEIN;

ADULT; AGE; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME IMMUNOASSAY; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; SPINE FRACTURE; WNT SIGNALING PATHWAY;

AGED; BETA CATENIN; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC MARKERS; HUMANS; MIDDLE AGED; OSTEOPOROSIS; RISK FACTORS; SPINAL FRACTURES; WNT SIGNALING PATHWAY;

EID: 84867259197     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-1901     Document Type: Article

References (43)

1. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL 2006 Risk of fracture in women with type 2 diabetes: the women's health initiative observational study. J Clin Endocrinol Metab 91:3404-3410 (Pubitemid 44402111)
2. Vestergaard P 2007 Discrepancies in bone and mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metanalysis. Osteoporos Int 18:427-444 (Pubitemid 46354916)
3. Epstein S, Leroith D 2008 Diabetes and fragility fractures: a burgeoning epidemic? Bone 43:3-6
4. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, Mc- Closkey E, Kanis JA 2012 FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res 27:301-308
5. Schwartz AV, Vittinghoff E, Bauer DC, Hillier TA, Strotmeyer ES, Ensrud KE, Donaldson MG, Cauley JA, Harris TB, Koster A, Womack CR, Palermo L, Black DM; Study of Osteoporotic Fractures (SOF) Research Group; Osteoporotic Fractures in Men (MrOS) Research Group; Health, Aging, and Body Composition (Health ABC) Research Group 2011 Association of BMD and FRAXscore with risk of fracture in older adults with type 2 diabetes. JAMA 305:2184-2192
6. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA, Muñoz-Torres M 2012 Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97:234-241
7. Welters HJ, Kulkarni RN 2008 Wnt signaling: relevance to β-cell biology and diabetes. Trends Endocrinol Metab 19:349-355
8. Day TF, Guo X, Garrett-Beal L, Yang Y 2005 Wnt/β-catenin in mesenchymal progenitor's controls osteoblast and chondrocyte differentiation during vertebrae skeletogenesis. Dev Cell 8:739-750 (Pubitemid 40585296)
9. Jian H, Shen X, Liu I, Semenov M, He X, Wang XF 2006 Smad3-dependent nuclear translocation of β-catenin is required for TGF-β1-induced proliferation of bone marrow-derived adult human mesenchymal stem cells. Genes Dev 20:666-674
10. Liu X, Li C, Liu K, Cui C, Zhang Y, Liu Y 2012 The influence of fluoride on the expression of inhibitors of Wnt/β-catenin signaling pathway in rat skin fibroblast cells. Biol Trace Elem Res 148:117-121
11. Moon RT, Kohn AD, De Ferrari GV, Kaykas A 2004 Wnt and β-catenin signaling: diseases and therapies. Nat Rev Genet 5:691-701 (Pubitemid 39150127)
12. Huang H, He X 2008 Wnt/β-catenin signaling: new (and old) players and new insight. Curr Opin Cell Biol 20:119-125
13. Kanazawa A, Tsukada S, Sekine A, Tsunoda T, Takahashi A, Kashiwagi A, Tanaka Y, Babazono T, Matsuda M, Kaku K, Iwamoto Y, Kawamori R, Kikkawa R, Nakamura Y, Maeda S 2004 Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 75:832-843 (Pubitemid 39390490)
14. Semënov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775
15. van Lierop AH, Hamdy NA, van der Meer RW, Jonker JT, Lamb HJ, Rijzewijk LJ, Rijzewijk LJ, Diamant M, Romijn JA, Smit JW, Papapoulos SE 2012 Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus. Eur J Endocrinol 166:711-716
16. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabrò A, Cataldo D, Stolakis K, Dotta F, Nuti R 2012 Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97:1737-1744
17. Xiong J, O'Brien CA 2012 Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res 27:499-505
18. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ 2011 Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 6:e25900
19. American Diabetes Association 2005 Diagnosis and classification of diabetes mellitus. Diabetes Care 28:S37-S42
20. Apolone G, Mosconi P 1998 The Italian SF-36 health survey: translation, validation and norming. J Clin Epidemiol 51:1025-1036 (Pubitemid 28527158)
21. Anderson RM, Fitzgerald JT, Wisdom K, Davis WK, Hiss RG 1997 A comparison of global vs disease-specific quality-of-life measures in patients with NIDDM. Diabetes Care 20:299-305 (Pubitemid 27098213)
22. Lin J, Curhan GC 2008 Kidney function decline and physical function in women. Nephrol Dial Transplant 23:2827-2833
23. Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, CummingsSR 1996 Comparison of semiquantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984-996 (Pubitemid 26200050)
24. Yamamoto M, Yamaguchi T, Nawata K, Yamauchi M, Sugimoto T 2012 Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 97:1277-1284
25. Melton 3rd LJ, Leibson CL, Achenbach SJ, Therneau TM, Khosla S 2008 Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334-1342 (Pubitemid 352040189)
26. Blakytny R, Spraul M, Jude EB 2011 Review: the diabetic bone: a cellular and a molecular perspective. Int J Low Extrem Wounds 10:16-32
27. de Paula FJ, Horowitz MC, Rosen CJ 2010 Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 26:622-630
28. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R 2010 Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutr Metab Cardiovasc Dis 20:683-690
29. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
30. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney Jr J, Laz-zaretti- Castro M, Silverberg SJ, Bilezikian JP 2011 Circulating sclerostin in disorders of parathyroid function. J Clin Endocrinol Metab 96:3804-3810
31. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
32. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton 3rd LJ, Khosla S 2011 Relation of age, gender, and bone mass to circulating sclerostin levels inwomenand men. J Bone Miner Res 26:373-379
33. Costa AG, Bilezikian JP 2012 Sclerostin: therapeutic horizons based upon its action. Curr Osteoporos Rep 10:64-72
34. Johnson ML, Kamel MA 2007 The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376-382 (Pubitemid 46884195)
35. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Löwik CW, ten Dijke P 2010 Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614-41626
36. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
37. Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W 1996 Functional interaction of (β)-catenin with the transcription factor LEF-1. Nature 382:638-642 (Pubitemid 26268958)
38. Devarajan-Ketha H, Craig TA, Madden BJ, Bergen 3rd HR, Kumar R 2012 The sclerostin-bone protein interactome. Biochem Biophys Res Commun 417:830-835 39.
39. van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE 2011 Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26:2804-2811
40. Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, Li Y, Feng G, Gao X, He L 2009 Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J Bone Miner Res 24:1651-1661
41. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583 (Pubitemid 41446595)
42. Yu EW, Kumbhani R, Siwila-Sackman E, Leder BZ 2011 Acute decline in serum sclerostin in response to PTH infusion in healthy men. J Clin Endocrinol Metab 96:1848-1851
43. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R 2011 Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 96:E1159-E1162